Callan Family Office LLC Takes $548,000 Position in Prestige Consumer Healthcare Inc. $PBH

Callan Family Office LLC acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 11,584 shares of the company’s stock, valued at approximately $548,000.

A number of other large investors have also recently added to or reduced their stakes in PBH. UMB Bank n.a. raised its position in Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after acquiring an additional 219 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Prestige Consumer Healthcare by 47.9% in the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock valued at $34,000 after purchasing an additional 235 shares during the last quarter. Torren Management LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $35,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Prestige Consumer Healthcare by 69.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after purchasing an additional 236 shares in the last quarter. Finally, Danske Bank A S purchased a new position in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $37,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PBH. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $51.38 on Wednesday. The business’s 50-day moving average price is $49.90 and its 200 day moving average price is $54.84. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $71.07. The company has a market capitalization of $2.43 billion, a PE ratio of 14.39, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. The company had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).